SCCA Clinical Studies: Lung Cancer
SCCA was formed, in part, to bring promising new treatments to patients faster. For lung cancer patients this means more treatment options are available at SCCA than might be found elsewhere, including participation in one of many ongoing clinical trials conducted at SCCA and its parent organizations, Fred Hutchinson Cancer Research Center and UW Medicine.
To find a clinical trial:
- View the Lung Cancer Trial Finder (pictured right), where trials are organized by disease status (e.g., Newly Diagnosed, Advanced Metastatic, etc).
- Click here to view a listing of all open lung cancer trials.
- To see a list of all of SCCA's most recently opened clinical trials, follow our Twitter feed @SCCA_Trials. Likewise, the SCCABlog also regularly lists recently opened trials as well.
Our current high priority trials include:
- MPDL3280A for PD-L1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (UW13041)
A Phase II, Multicenter, Single-Arm study of MPDL3280A in Patients with PD-L1-Positive Locally Advanced or Metastatic Non-Small Cell lung Cancer
- Alisertib (MLN8237) in Combination With Paclitaxel for Small Cell Lung Cancer (UW14002)
A Randomized, Double-blind, Placebo-controlled, Phase 2 Clinical Trial of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)